&nbsp;

Drugs Used:

letrozole

Quick Link(s):

Regimen Monograph

Oct 2025

Regimen

ABEMANAS

Cancer Type:

Breast

Intent: Adjuvant, Palliative

Funding:

Exceptional Access Program

ODB - General Benefit

anastrozole

Drugs Used:

anastrozole

Quick Link(s):

Regimen Monograph

Oct 2025

Regimen

AXIT+PEMB

Cancer Type:

Genitourinary,

Renal cell / Kidney

Intent: Palliative

Funding:

Exceptional Access Program

aXitinib - In combination with pembrolizumab for first-line advanced or metastatic renal cell carcinoma

New Drug Funding Program

Pembrolizumab - In Combination with Axitinib for First Line Advanced or Metastatic Renal Cell Carcinoma

Drugs Used:

aXitinib,

pembrolizumab

Quick Link(s):

Regimen Monograph

Aug 2023

Regimen

AZCTVENE

Cancer Type:

Hematologic,

Leukemia - Acute Myeloid (AML)

Intent: Palliative

Funding:

New Drug Funding Program

Azacitidine in combination with Venetoclax (Outpatient) - Previously Untreated Acute Myeloid Leukemia

Exceptional Access Program

venetoclax - Venetoclax in combination with azacitidine - Previously untreated acute myeloid leukemia

Drugs Used:

azaCITIDine,

venetoclax

Quick Link(s):

Regimen Monograph

Aug 2022

Regimen

AZCT(MNT-PO)

Cancer Type:

Hematologic,

Leukemia - Acute Myeloid (AML)

Intent: Palliative

Funding:

Exceptional Access Program

azaCITIDine (tablets) - For maintenance therapy in adult patients with AML who achieved complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following induction therapy with or without consolidation treatment, and who are not eligible for hematopoietic stem cell transplantation

Drugs Used:

azaCITIDine (tablets)

Quick Link(s):

Regimen Monograph

Jul 2023

Drug

azaCITIDine (tablets)

Other Name(s): Onureg®

Quick Link(s): Drug Monograph, Patient Info Sheet

Aug 2023

Regimen

ABEMEXEM

Cancer Type:

Breast

Intent: Adjuvant

Funding:

Exceptional Access Program

ODB - General Benefit

exemestane

Drugs Used:

exemestane

Quick Link(s):

Regimen Monograph

Oct 2025

Regimen

ABEMTMXF

Cancer Type:

Breast

Intent: Adjuvant

Funding:

Exceptional Access Program

ODB - General Benefit

tamoxifen

Drugs Used:

tamoxifen

Quick Link(s):

Regimen Monograph

Oct 2025

Regimen

ABIRNIRPPRED

Cancer Type:

Genitourinary,

Prostate

Intent: Palliative

Funding:

Exceptional Access Program

niraparib / abiraterone - For the treatment of metastatic castration resistant prostate cancer in patients with a BRCA mutation

ODB - General Benefit

prednisone

Drugs Used:

niraparib / abiraterone,

prednisone

Quick Link(s):

Regimen Monograph

Jun 2025

Regimen

ABIROLAPPRED

Cancer Type:

Genitourinary,

Prostate

Intent: Palliative

Funding:

ODB - General Benefit

abiraterone

Exceptional Access Program

olaparib - In combination with abiraterone, and prednisone or prednisolone for the treatment of metastatic castration resistant prostate cancer (mCRPC), based on criteria

ODB - General Benefit

prednisone

Drugs Used: